<DOC>
	<DOCNO>NCT02375971</DOCNO>
	<brief_summary>The purpose study determine intravitreal ranibizumab superior laser ablation therapy treatment retinopathy prematurity ( ROP ) .</brief_summary>
	<brief_title>RAINBOW Study : RAnibizumab Compared With Laser Therapy Treatment INfants BOrn Prematurely With Retinopathy Prematurity</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Preterm infant birth weight less 1500 g Bilateral ROP 1 follow retinal finding eye : Zone I , stage 1+ , 2+ , 3 3+ disease , Zone II , stage 3+ disease , Aggressive posterior ROP Have receive previous surgical nonsurgical treatment ROP ( e.g. , ablative laser therapy cryotherapy , vitrectomy ) Have previously expose intravitreal systemic antiVEGF agent ( either patient mother child 's pregnancy ) Have ocular structural abnormality assess Investigator clinically significant impact study assessment Have active ocular infection within 5 day day first investigational treatment Have medical condition clinically significant comorbidities personal circumstance assess Investigator clinically relevant impact study participation , study procedure , efficacy assessment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>intravitreal ranibizumab</keyword>
	<keyword>laser ablation therapy</keyword>
	<keyword>retinopathy prematurity</keyword>
	<keyword>preterm infant</keyword>
	<keyword>RAINBOW</keyword>
</DOC>